2022 Annual Shareholders' Meeting Results

Stock Exchange Announcement
STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)

2022 Annual Shareholders’ Meeting Results

Auckland, New Zealand, 24 August 2022 - Fisher & Paykel Healthcare Corporation Limited advises that all resolutions put to the company’s annual shareholders’ meeting held today were passed. The 11 resolutions were:
Resolution 1: To re-elect Lewis Gradon as a director.
Resolution 2: To re-elect Neville Mitchell as a director.
Resolution 3: To re-elect Donal O’Dwyer as a director.
Resolution 4: To elect Lisa McIntyre as a director.
Resolution 5: To elect Cather Simpson as a director.
Resolution 6: To authorise the Directors to fix the fees and expenses of the auditor.
Resolution 7: To approve the issue of performance share rights to Lewis Gradon.
Resolution 8: To approve the issue of options to Lewis Gradon.
Resolution 9: To approve the North America 2022 Employee Stock Purchase Plan.
Resolution 10: To approve the 2022 Performance Share Rights Plan – North America.
Resolution 11: To approve the 2022 Performance Share Option Plan – North America.
All resolutions were decided by poll. The details of the total number of votes cast online, via phone or by proxy on the polls were as follows:

Resolution Votes
Resolution 1: To re-elect Lewis Gradon as a director
For: 417,970,319 (99.99%); Against: 30,222; Abstain: 83,434; Total: 418,083,975
Resolution 2: To re-elect Neville Mitchell as a director
For: 411,128,146 (98.36%); Against: 6,860,053; Abstain: 95,776; Total: 418,083,975
Resolution 3: To re-elect Donal O’Dwyer as a director
For: 410,700,203 (98.28%); Against: 7,177,829; Abstain: 205,943; Total: 418,083,975
Resolution 4: To elect Lisa McIntyre as a director
For: 417,824,318 (99.99%); Against: 56,047; Abstain: 203,610; Total: 418,083,975
Resolution 5: To elect Cather Simpson as a director
For: 417,779,788 (99.97%); Against: 105,828; Abstain: 198,359; Total: 418,083,975
Resolution 6: To authorise the Directors to fix the fees and expenses of the auditor
For: 412,820,609 (99.30%); Against: 2,902,593; Abstain: 2,360,773; Total: 418,083,975
Resolution 7: To approve the issue of performance share rights to Lewis Gradon
For: 406,452,228 (97.42%); Against: 10,773,351; Abstain: 294,521; Total: 417,520,100
Resolution 8: To approve the issue of options to Lewis Gradon
For: 406,325,338 (97.39%); Against: 10,895,306; Abstain: 299,376; Total: 417,520,020
Resolution 9: To approve the 2022 Employee Stock Purchase Plan
For: 416,172,287 (99.59%); Against: 1,715,840; Abstain: 195,848; Total: 418,083,975
Resolution 10: To approve the 2022 Performance Share Rights Plan – North America
For: 415,456,483 (99.44%); Against: 2,358,647; Abstain: 267,250; Total:418,082,380
Resolution 11: To approve the 2022 Performance Share Option Plan – North America
For: 416,914,483 (99.81%); Against: 813,161; Abstain: 354,656; Total: 418,082,300

About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company’s products are sold in over 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.

Media & Investor Contacts:

Karen Knott
GM Corporate Communications
[email protected]
+64 21 713 911

Hayden Brown
Investor Relations Manager
[email protected]
+64 27 807 8073

Authorised by Raelene Leonard, General Counsel & Company Secretary.

---

Announcement PDF